Premiere Oncology of Arizona

Scottsdale, Arizona 85260

0 studies enrolling now · 23 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Cancer, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Castration-Resistant Prostate Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Impaired Hepatic Function, Lymphedema, Malignancy

Studies at this site

• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer — Completed
• Evaluating Patients With Varying Degrees of Renal Function — Completed
• A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors — Completed
• Evaluating Patients With Impaired Hepatic Function — Completed
• Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy — Completed
• Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC — Completed
• Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer — Completed
• A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors — Stopped early
• A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma — Stopped early
• Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin — Completed
• Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors — Completed
• Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma — Completed
• Safety and Efficacy Study of Glufosfamide in Ovarian Cancer — Stopped early
• Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors — Completed
• A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors — Completed
• Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors — Completed
• Study of XL281 in Adults With Solid Tumors — Completed
• Cardiac Safety Assessment Study of Picoplatin in Solid Tumors — Status unconfirmed
• Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma — Completed
• Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma — Completed
• Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors — Completed
• DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2]) — Stopped early
• Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema — Status unconfirmed